185 related articles for article (PubMed ID: 26852175)
1. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
[TBL] [Abstract][Full Text] [Related]
2. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
[TBL] [Abstract][Full Text] [Related]
3. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
5. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
6. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
7. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CI; Sander B
Leukemia; 2003 Sep; 17(9):1880-90. PubMed ID: 12970790
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
10. The TERT Promoter: A Key Player in the Fight for Cancer Cell Immortality.
Hasanau TN; Pisarev EP; Kisil OV; Zvereva ME
Biochemistry (Mosc); 2023 Jan; 88(Suppl 1):S21-S38. PubMed ID: 37069112
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas.
Navarro A; Beà S; Fernández V; Prieto M; Salaverria I; Jares P; Hartmann E; Mozos A; López-Guillermo A; Villamor N; Colomer D; Puig X; Ott G; Solé F; Serrano S; Rosenwald A; Campo E; Hernández L
Cancer Res; 2009 Sep; 69(17):7071-8. PubMed ID: 19690137
[TBL] [Abstract][Full Text] [Related]
15. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.
Dratwa M; Wysoczanska B; Turlej E; Anisiewicz A; Maciejewska M; Wietrzyk J; Bogunia-Kubik K
Exp Cell Res; 2020 Nov; 396(1):112298. PubMed ID: 32971118
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
19. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
20. A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients.
Li X; Wu N; Li B
Medicine (Baltimore); 2019 May; 98(22):e15811. PubMed ID: 31145313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
